Version May 2024
Ocular disorders: Ophthalmic: Instill 1 to 2 drops in each affected eye 4 times daily
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
Refer to adult dosing.
Ocular disorders: Ophthalmic: Children ≥2 years: Refer to adult dosing.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%: Ophthalmic: Burning sensation of eyes (transient), eye discomfort (transient), stinging of eyes (transient)
1% to 10%:
Central nervous system: Foreign body sensation of eye, headache
Ophthalmic: Blurred vision, crystalline eye deposits, eye pruritus, lacrimation, ocular hyperemia, ocular edema, xerophthalmia
1%, postmarketing, and/or case reports: Asthenopia, blepharitis, chemosis, corneal abrasion, corneal erosion, corneal ulcer, dizziness, drowsiness, dry nose, epitheliopathy, eye pain, keratitis, nausea, ocular warming sensation, skin rash, sneezing, stomach discomfort, swelling of eye
Hypersensitivity to lodoxamide or any component of the formulation
Concerns related to adverse effects:
• Irritation: May cause discomfort or transient burning or stinging upon instillation.
• Ocular effects: May cause temporary blurred vision or other visual disturbances; caution patients to wait until vision clears before driving or operating machinery.
Special populations:
• Contact lens wearers: Contains benzalkonium chloride which may be absorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.
Other warnings/precautions:
• Appropriate use: For topical ophthalmic use only; not for injection. To avoid contamination, do not touch dropper tip to eyelids or other surfaces when placing drops in eyes.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, Ophthalmic:
Alomide: 0.1% (10 mL [DSC])
No
Solution (Alomide Ophthalmic)
0.1% (per mL): $23.69
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic:
Alomide: 0.1% (10 mL) [contains benzalkonium chloride, edetate (edta) disodium]
For topical ophthalmic use only, not for injection. Wash hands before use. To avoid contamination, do not touch dropper tip to eyelids or other surfaces when placing drops in eyes. Remove contact lenses prior to administration. Wait 15 minutes or longer before reinserting lenses.
Ophthalmic: For topical ophthalmic use only, not for injection. Wash hands before use. To avoid contamination, do not touch dropper tip to eyelids or other surfaces when placing drops in eyes. Solution contains benzalkonium chloride; remove contact lenses prior to administration and wait at least 15 minutes after instillation before reinserting lenses.
Ocular disorders: Treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis
Thilomide [Greece, Turkey] may be confused with Thalomid brand name for thalidomide [US, Canada]
None known.
There are no known significant interactions.
Adverse events have not been observed in animal reproduction studies following oral administration. The amount of lodoxamide available systemically following ophthalmic administration is below the level of detection.
It is not known if lodoxamide is excreted in breast milk. The manufacturer recommends that caution be exercised when administering lodoxamide to nursing women.
Mast cell stabilizer that inhibits the in vivo type I immediate hypersensitivity reaction to increase cutaneous vascular permeability associated with IgE and antigen-mediated reactions
Absorption: Topical: Negligible
Half-life elimination: 8.5 hours
Excretion: Urine
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
